Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?-Reference-Cited by-同舟云学术

Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?

Published:2009-01 Issue:1 Volume:24 Page:88-94
ISSN:0268-4705
Container-title:Current Opinion in Cardiology
language:en
Short-container-title:

Author:

Cohen Marc,Ferguson James J

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference36 articles.

1. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention);Smith;J Am Coll Cardiol,2006

2. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 Randomized Trial;Kastrati;J Am Med Assoc,2006

3. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group;Ellis;Circulation,1990

4. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions Lesion Classification System in the current ‘Stent Era’ of coronary interventions (from the ACC-National Cardiovascular Data Registry);Krone;Am J Cardiol,2003

5. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the mayo clinic from 1994 to 2005;Doyle;J Am Coll Cardiol Intv,2008

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. α-Lipoic acid alleviates myocardial injury and induces M2b macrophage polarization after myocardial infarction via HMGB1/NF-kB signaling pathway;International Immunopharmacology;2023-08

2. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial;European Heart Journal;2018-09-09

3. Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial;EuroIntervention;2016-07

4. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome;The American Journal of Cardiology;2013-02

5. Comparison of Frequency of Periprocedural Myocardial Infarction in Patients With and Without Diabetes Mellitus to Those With Previously Unknown but Elevated Glycated Hemoglobin Levels (from the TWENTE Trial);The American Journal of Cardiology;2012-12